BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 30422669)

  • 1. Tumor-derived Autoantibodies Identify Malignant Pulmonary Nodules.
    Lastwika KJ; Kargl J; Zhang Y; Zhu X; Lo E; Shelley D; Ladd JJ; Wu W; Kinahan P; Pipavath SNJ; Randolph TW; Shipley M; Lampe PD; Houghton AM
    Am J Respir Crit Care Med; 2019 May; 199(10):1257-1266. PubMed ID: 30422669
    [No Abstract]   [Full Text] [Related]  

  • 2. Comparative Study of Autoantibody Responses between Lung Adenocarcinoma and Benign Pulmonary Nodules.
    Wang J; Shivakumar S; Barker K; Tang Y; Wallstrom G; Park JG; Tsay JC; Pass HI; Rom WN; LaBaer J; Qiu J
    J Thorac Oncol; 2016 Mar; 11(3):334-45. PubMed ID: 26896032
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Significance of tumor-associated autoantibodies in the early diagnosis of lung cancer.
    Du Q; Yu R; Wang H; Yan D; Yuan Q; Ma Y; Slamon D; Hou D; Wang H; Wang Q
    Clin Respir J; 2018 Jun; 12(6):2020-2028. PubMed ID: 29356386
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Autoantibody Signature Enhances the Positive Predictive Power of Computed Tomography and Nodule-Based Risk Models for Detection of Lung Cancer.
    Massion PP; Healey GF; Peek LJ; Fredericks L; Sewell HF; Murray A; Robertson JF
    J Thorac Oncol; 2017 Mar; 12(3):578-584. PubMed ID: 27615397
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Gene Expression Classifier from Whole Blood Distinguishes Benign from Malignant Lung Nodules Detected by Low-Dose CT.
    Kossenkov AV; Qureshi R; Dawany NB; Wickramasinghe J; Liu Q; Majumdar RS; Chang C; Widura S; Kumar T; Horng WH; Konnisto E; Criner G; Tsay JJ; Pass H; Yendamuri S; Vachani A; Bauer T; Nam B; Rom WN; Showe MK; Showe LC
    Cancer Res; 2019 Jan; 79(1):263-273. PubMed ID: 30487137
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A model based on the quantification of complement C4c, CYFRA 21-1 and CRP exhibits high specificity for the early diagnosis of lung cancer.
    Ajona D; Remirez A; Sainz C; Bertolo C; Gonzalez A; Varo N; Lozano MD; Zulueta JJ; Mesa-Guzman M; C Martin A; Perez-Palacios R; Perez-Gracia JL; Massion PP; Montuenga LM; Pio R
    Transl Res; 2021 Jul; 233():77-91. PubMed ID: 33618009
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preoperative diagnosis of malignant pulmonary nodules in lung cancer screening with a radiomics nomogram.
    Liu A; Wang Z; Yang Y; Wang J; Dai X; Wang L; Lu Y; Xue F
    Cancer Commun (Lond); 2020 Jan; 40(1):16-24. PubMed ID: 32125097
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serum Protein Markers for the Early Detection of Lung Cancer: A Focus on Autoantibodies.
    Broodman I; Lindemans J; van Sten J; Bischoff R; Luider T
    J Proteome Res; 2017 Jan; 16(1):3-13. PubMed ID: 27769114
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development and validation of a plasma biomarker panel for discerning clinical significance of indeterminate pulmonary nodules.
    Daly S; Rinewalt D; Fhied C; Basu S; Mahon B; Liptay MJ; Hong E; Chmielewski G; Yoder MA; Shah PN; Edell ES; Maldonado F; Bungum AO; Borgia JA
    J Thorac Oncol; 2013 Jan; 8(1):31-6. PubMed ID: 23201823
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Malignancy risk estimation of screen-detected nodules at baseline CT: comparison of the PanCan model, Lung-RADS and NCCN guidelines.
    van Riel SJ; Ciompi F; Jacobs C; Winkler Wille MM; Scholten ET; Naqibullah M; Lam S; Prokop M; Schaefer-Prokop C; van Ginneken B
    Eur Radiol; 2017 Oct; 27(10):4019-4029. PubMed ID: 28293773
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combining serum miRNAs, CEA, and CYFRA21-1 with imaging and clinical features to distinguish benign and malignant pulmonary nodules: a pilot study : Xianfeng Li et al.: Combining biomarker, imaging, and clinical features to distinguish pulmonary nodules.
    Li X; Zhang Q; Jin X; Cao L
    World J Surg Oncol; 2017 May; 15(1):107. PubMed ID: 28545454
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Value of a Seven-Autoantibody Panel Combined with the Mayo Model in the Differential Diagnosis of Pulmonary Nodules.
    Ling Z; Chen J; Wen Z; Wei X; Su R; Tang Z; Hu Z
    Dis Markers; 2021; 2021():6677823. PubMed ID: 33688380
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Assessment of indeterminate pulmonary nodules detected in lung cancer screening: Diagnostic accuracy of FDG PET/CT.
    Garcia-Velloso MJ; Bastarrika G; de-Torres JP; Lozano MD; Sanchez-Salcedo P; Sancho L; Nuñez-Cordoba JM; Campo A; Alcaide AB; Torre W; Richter JA; Zulueta JJ
    Lung Cancer; 2016 Jul; 97():81-6. PubMed ID: 27237032
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Value of Combined Detection of Cytokines and Tumor Markers in the 
Differential Diagnosis of Benign and Malignant Solitary Pulmonary Nodules].
    Shi J; Liu X; Ming Z; Li W; Lv X; Yang X; Wang Y; Zhang M; Yang S
    Zhongguo Fei Ai Za Zhi; 2021 Jun; 24(6):426-433. PubMed ID: 34157802
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Therapeutic strategy in patients with non-small cell lung cancer associated to satellite pulmonary nodules.
    Carretta A; Ciriaco P; Canneto B; Nicoletti R; Del Maschio A; Zannini P
    Eur J Cardiothorac Surg; 2002 Jun; 21(6):1100-4. PubMed ID: 12048092
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serological proteome analysis approach-based identification of ENO1 as a tumor-associated antigen and its autoantibody could enhance the sensitivity of CEA and CYFRA 21-1 in the detection of non-small cell lung cancer.
    Dai L; Qu Y; Li J; Wang X; Wang K; Wang P; Jiang BH; Zhang J
    Oncotarget; 2017 May; 8(22):36664-36673. PubMed ID: 28456790
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A prediction model based on DNA methylation biomarkers and radiological characteristics for identifying malignant from benign pulmonary nodules.
    Xing W; Sun H; Yan C; Zhao C; Wang D; Li M; Ma J
    BMC Cancer; 2021 Mar; 21(1):263. PubMed ID: 33691657
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Positron emission tomography in the diagnostic work-up of screening-detected lung nodules.
    Veronesi G; Travaini LL; Maisonneuve P; Rampinelli C; Bertolotti R; Spaggiari L; Bellomi M; Paganelli G
    Eur Respir J; 2015 Feb; 45(2):501-10. PubMed ID: 25261326
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Are circulating autoantibodies to ABCC3 transporter a potential biomarker for lung cancer?
    Liu L; Liu N; Liu B; Yang Y; Zhang Q; Zhang W; Yu P; Jin Y; Guo J; Guan S; Sun S; Miao L; Wei J
    J Cancer Res Clin Oncol; 2012 Oct; 138(10):1737-42. PubMed ID: 22699933
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lung nodule detection in a high-risk population: comparison of magnetic resonance imaging and low-dose computed tomography.
    Sommer G; Tremper J; Koenigkam-Santos M; Delorme S; Becker N; Biederer J; Kauczor HU; Heussel CP; Schlemmer HP; Puderbach M
    Eur J Radiol; 2014 Mar; 83(3):600-5. PubMed ID: 24364923
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.